Opendata, web and dolomites

ONCO-VAX SIGNED

A multifaceted cancer immunotherapy based on an immune checkpoint-modulating chimeric oncolytic virus vector in combination with a dendritic cell vaccine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ONCO-VAX project word cloud

Explore the words cloud of the ONCO-VAX project. It provides you a very rough idea of what is the project "ONCO-VAX" about.

medical    microenvironment    immunotherapy    successful    societal    disappointing    spread    multifaceted    carcinoma    optimized    dendritic    oncolytic    liver    platform    onco    vax    combined    immuno    solid    strategy    immunity    stimulatory    scheme    tumors    worldwide    mass    monotherapeutics    patients    financially    spreading    layer    shift    utilized    gene    edge    cell    treat    combination    innate    disease    systemic    hcc    cancer    eradicating    express    replication    elegant    restricts    multimodal    lysis    decades    health    cutting    nevertheless    oncology    immune    subset    therapeutic    ovs    synergistic    intensive    directed    enhanced    viruses    broad    virus    backbone    therapy    initiate    intratumoral    burden    antitumor    capacity    mechanism    epidemiologically    combat    hepatocellular    despite    malignancy    dramatic    innovative    potentially    direct    vaccine    life    basis    antiviral    patient    stimulating    local    treating    employ    reaching    metastatic    transforming    inherently    suppressive    imposes    limited    ov    paradigm    tumor    additional    heavy    chimeric   

Project "ONCO-VAX" data sheet

The following table provides information about the project.

Coordinator
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN 

Organization address
address: ISMANINGER STRASSE 22
city: MUENCHEN
postcode: 81675
website: http://www.med.tu.muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙988 €
 EC max contribution 1˙499˙988 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2025-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) coordinator 1˙499˙988.00

Map

 Project objective

Despite many decades of intensive research, cancer remains a major worldwide health concern and imposes a heavy societal burden, both epidemiologically and financially. Cancer immunotherapy is rapidly transforming the face of medical oncology as an exciting paradigm shift in treating cancer by exploiting the immune system of the patient as the basis for the therapy. Although dramatic results have been achieved in a subset of patients, the responses in most solid tumors have been disappointing. Hepatocellular carcinoma (HCC) represents a particularly challenging malignancy to treat, due to the inherently immune-suppressive microenvironment in the liver. Oncolytic viruses (OVs) offer an elegant multimodal approach to combat HCC through their ability to cause direct tumor cell lysis, while stimulating immune responses directed against the tumor. Nevertheless, the potential of OVs as monotherapeutics is limited by the innate antiviral immune response, which rapidly restricts virus replication and spread within the tumor mass. Therefore, a successful therapeutic strategy should employ a combination scheme involving a mechanism to improve the intratumoral dissemination of the OV, while exploiting the immune-stimulatory capacity of the virus, in order to achieve far-reaching synergistic responses that can target metastatic disease. The ONCO-VAX approach aims to accomplish just that. A novel chimeric oncolytic virus backbone with an enhanced cell-cell spreading capacity, will be utilized as a platform to express an optimized gene for eradicating the local immune-suppressive microenvironment in the tumor. As an additional layer of therapy, the virus will be combined with a cutting edge dendritic cell vaccine approach to initiate a broad antitumor response for systemic and potentially life-long immunity against the cancer. This multifaceted approach represents an innovative and crucial step forward in the rapidly evolving field of cancer immuno-oncology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCO-VAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCO-VAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More